ESR1 and neoplasm: In the mouse, Sox9 has been shown to be a key re-gulator of mammary gland development and stem/progenitor cell maintenance [18] and, in breast cancer patients, high-Sox9 expression has been associated with estrogen receptor (ER)-negative tumours, significantly shorter overall survival and poor survival [19].